Symbols / ANNX
ANNX Chart
About
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 739.32M |
| Enterprise Value | 431.60M | Income | -208.88M | Sales | — |
| Book/sh | 1.40 | Cash/sh | 1.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 99 | IPO | — |
| P/E | — | Forward P/E | -4.17 | PEG | — |
| P/S | — | P/B | 3.54 | P/C | — |
| EV/EBITDA | -1.99 | EV/Sales | — | Quick Ratio | 4.33 |
| Current Ratio | 4.42 | Debt/Eq | 16.69 | LT Debt/Eq | — |
| EPS (ttm) | -1.41 | EPS next Y | -1.19 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 | ROA | -44.95% |
| ROE | -83.98% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 149.06M |
| Shs Float | 95.87M | Short Float | 13.54% | Short Ratio | 6.63 |
| Short Interest | — | 52W High | 7.18 | 52W Low | 1.28 |
| Beta | 1.14 | Avg Volume | 2.57M | Volume | 2.67M |
| Target Price | $14.33 | Recom | Strong_buy | Prev Close | $4.89 |
| Price | $4.96 | Change | 1.43% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.33
Mean price target
2. Current target
$4.96
Latest analyst target
3. DCF / Fair value
$-11.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.96
Low
$8.00
High
$27.00
Mean
$14.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-23 | init | Chardan Capital | — → Buy | $16 |
| 2025-12-02 | init | Clear Street | — → Buy | $17 |
| 2025-11-19 | main | Wells Fargo | Overweight → Overweight | $27 |
| 2025-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-05-14 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-05-13 | main | Needham | Buy → Buy | $11 |
| 2025-03-04 | reit | Needham | Buy → Buy | $16 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-11-15 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-11-15 | reit | Needham | Buy → Buy | $16 |
| 2024-09-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-13 | reit | Needham | Buy → Buy | $16 |
| 2024-06-05 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-06-04 | reit | Needham | Buy → Buy | $16 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-05-15 | main | Wells Fargo | Overweight → Overweight | $10 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-05-13 | reit | Needham | Buy → Buy | $16 |
- Could vonaprument preserve sight in GA? Annexon gathers eye experts March 18 - Stock Titan ue, 17 Feb 2026 13
- $ANNX stock is up 2% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
- Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases - Seeking Alpha Sat, 24 Jan 2026 08
- Annexon Leadership Makes Bold Move With Coordinated Stock Sales - TipRanks Sat, 21 Feb 2026 02
- Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement - Yahoo Finance Fri, 28 Nov 2025 08
- Independent Director of Annexon Jung Choi Buys More Stock - simplywall.st Fri, 05 Dec 2025 08
- Satter Muneer a buys Annexon (ANNX) shares worth $5m - Investing.com Wed, 19 Nov 2025 08
- $ANNX stock is down 4% today. Here's what we see in our data. - Quiver Quantitative ue, 25 Nov 2025 08
- Annexon (NASDAQ: ANNX) on track for January 2026 GBS MAA filing; cash stands at $188.7M - Stock Titan Mon, 10 Nov 2025 08
- Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX? - Yahoo Finance ue, 20 Jan 2026 08
- Satter Muneer buys Annexon (ANNX) shares worth $3.6 million - Investing.com Fri, 21 Nov 2025 08
- $ANNX stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development - Yahoo Finance Wed, 17 Dec 2025 08
- Insider Purchase: Director at $ANNX Buys 500,000 Shares - Quiver Quantitative hu, 20 Nov 2025 08
- Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition - Yahoo Finance ue, 30 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 62500 | — | — | Stock Award(Grant) at price 0.00 per share. | ARTIS DEAN RICHARD PH.D. | Officer | — | 2026-02-19 00:00:00 | D |
| 1 | 6225 | 31748 | — | Sale at price 5.10 per share. | OVERDORF MICHAEL | Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 7857 | 40149 | — | Sale at price 5.11 per share. | YEDNOCK TED | Chief Technology Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 5290 | 26979 | — | Sale at price 5.10 per share. | ARTIS DEAN RICHARD PH.D. | Officer | — | 2026-02-18 00:00:00 | D |
| 4 | 7851 | 40119 | — | Sale at price 5.11 per share. | LEW JENNIFER | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 5 | 5290 | 26979 | — | Sale at price 5.10 per share. | DANANBERG JAMIE | Officer | — | 2026-02-18 00:00:00 | D |
| 6 | 4115 | 20657 | — | Purchase at price 5.02 per share. | CARSON WILLIAM H. | Director | — | 2025-12-30 00:00:00 | D |
| 7 | 4115 | 18394 | — | Purchase at price 4.47 per share. | CARSON WILLIAM H. | Director | — | 2025-12-01 00:00:00 | D |
| 8 | 33000 | 138270 | — | Purchase at price 4.19 per share. | CHOI JUNG E. | Director | — | 2025-12-01 00:00:00 | I |
| 9 | 4115 | 13045 | — | Purchase at price 3.17 per share. | CARSON WILLIAM H. | Director | — | 2025-10-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -151.47M | -141.57M | -143.45M | -128.57M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -138.20M | -134.24M | -141.95M | -130.32M |
| ReconciledDepreciation | 2.15M | 2.15M | 2.11M | 2.14M |
| EBITDA | -151.47M | -141.57M | -143.45M | -128.57M |
| EBIT | -154.07M | -143.72M | -145.60M | -130.71M |
| NetInterestIncome | 15.87M | 9.49M | 3.65M | 390.00K |
| InterestIncome | 15.87M | 9.49M | 3.65M | 390.00K |
| NormalizedIncome | -138.20M | -134.24M | -141.95M | -130.32M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -138.20M | -134.24M | -141.95M | -130.32M |
| TotalExpenses | 154.07M | 143.72M | 145.60M | 130.71M |
| TotalOperatingIncomeAsReported | -154.07M | -143.72M | -145.60M | -130.71M |
| DilutedAverageShares | 137.40M | 75.67M | 54.67M | 38.32M |
| BasicAverageShares | 137.40M | 75.67M | 54.67M | 38.32M |
| DilutedEPS | -1.01 | -1.77 | -2.60 | -3.40 |
| BasicEPS | -1.01 | -1.77 | -2.60 | -3.40 |
| DilutedNIAvailtoComStockholders | -138.20M | -134.24M | -141.95M | -130.32M |
| NetIncomeCommonStockholders | -138.20M | -134.24M | -141.95M | -130.32M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -138.20M | -134.24M | -141.95M | -130.32M |
| NetIncomeIncludingNoncontrollingInterests | -138.20M | -134.24M | -141.95M | -130.32M |
| NetIncomeContinuousOperations | -138.20M | -134.24M | -141.95M | -130.32M |
| PretaxIncome | -138.20M | -134.24M | -141.95M | -130.32M |
| NetNonOperatingInterestIncomeExpense | 15.87M | 9.49M | 3.65M | 390.00K |
| InterestIncomeNonOperating | 15.87M | 9.49M | 3.65M | 390.00K |
| OperatingIncome | -154.07M | -143.72M | -145.60M | -130.71M |
| OperatingExpense | 154.07M | 143.72M | 145.60M | 130.71M |
| DepreciationAmortizationDepletionIncomeStatement | 2.60M | 1.95M | 2.15M | |
| DepreciationAndAmortizationInIncomeStatement | 2.60M | 1.95M | 2.15M | |
| DepreciationIncomeStatement | 2.60M | 1.95M | 2.15M | |
| ResearchAndDevelopment | 119.45M | 113.76M | 112.50M | 100.07M |
| SellingGeneralAndAdministration | 32.03M | 28.02M | 30.95M | 30.65M |
| GeneralAndAdministrativeExpense | 32.03M | 28.02M | 30.95M | 30.65M |
| OtherGandA | 15.17M | 11.62M | 13.76M | 16.92M |
| SalariesAndWages | 16.86M | 16.40M | 17.19M | 13.73M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 109.38M | 78.37M | 47.72M | 38.56M |
| ShareIssued | 109.38M | 78.37M | 47.72M | 38.56M |
| TotalDebt | 28.97M | 31.36M | 32.86M | 34.59M |
| TangibleBookValue | 293.11M | 250.56M | 231.19M | 231.91M |
| InvestedCapital | 293.11M | 250.56M | 231.19M | 231.91M |
| WorkingCapital | 285.95M | 245.93M | 225.74M | 225.95M |
| NetTangibleAssets | 293.11M | 250.56M | 231.19M | 231.91M |
| CapitalLeaseObligations | 28.97M | 31.36M | 32.86M | 34.59M |
| CommonStockEquity | 293.11M | 250.56M | 231.19M | 231.91M |
| TotalCapitalization | 293.11M | 250.56M | 231.19M | 231.91M |
| TotalEquityGrossMinorityInterest | 293.11M | 250.56M | 231.19M | 231.91M |
| StockholdersEquity | 293.11M | 250.56M | 231.19M | 231.91M |
| GainsLossesNotAffectingRetainedEarnings | 10.00K | -52.00K | -372.00K | -180.00K |
| OtherEquityAdjustments | 10.00K | -52.00K | -372.00K | -180.00K |
| RetainedEarnings | -710.70M | -572.50M | -438.26M | -296.31M |
| AdditionalPaidInCapital | 1.00B | 823.03M | 669.78M | 528.37M |
| CapitalStock | 109.00K | 78.00K | 48.00K | 39.00K |
| CommonStock | 109.00K | 78.00K | 48.00K | 39.00K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 56.97M | 47.12M | 53.90M | 55.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.45M | 29.19M | 31.54M | 33.39M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 26.45M | 29.19M | 31.54M | 33.39M |
| LongTermCapitalLeaseObligation | 26.45M | 29.19M | 31.54M | 33.39M |
| CurrentLiabilities | 30.51M | 17.93M | 22.36M | 21.74M |
| OtherCurrentLiabilities | 141.00K | 141.00K | 180.00K | 139.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 2.52M | 2.17M | 1.32M | 1.20M |
| CurrentCapitalLeaseObligation | 2.52M | 2.17M | 1.32M | 1.20M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.83M | 5.61M | 5.30M | 3.57M |
| PayablesAndAccruedExpenses | 22.02M | 10.02M | 15.56M | 16.83M |
| CurrentAccruedExpenses | 11.59M | 4.53M | 8.15M | 5.68M |
| Payables | 10.43M | 5.49M | 7.42M | 11.15M |
| AccountsPayable | 10.43M | 5.49M | 7.42M | 11.15M |
| TotalAssets | 350.07M | 297.67M | 285.10M | 287.04M |
| TotalNonCurrentAssets | 33.61M | 33.81M | 37.00M | 39.35M |
| OtherNonCurrentAssets | 4.27M | 1.03M | 1.03M | 1.17M |
| NetPPE | 29.34M | 32.78M | 35.97M | 38.18M |
| AccumulatedDepreciation | -7.18M | -5.03M | -2.88M | -789.00K |
| GrossPPE | 36.52M | 37.81M | 38.85M | 38.97M |
| Leases | 17.25M | 17.25M | 17.23M | 16.59M |
| OtherProperties | 18.54M | 19.84M | 20.89M | 21.69M |
| MachineryFurnitureEquipment | 725.00K | 725.00K | 726.00K | 690.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 316.46M | 263.86M | 248.10M | 247.69M |
| OtherCurrentAssets | 1.10M | 823.00K | 203.00K | 463.00K |
| PrepaidAssets | 3.34M | 3.32M | 5.24M | 4.51M |
| Receivables | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 312.02M | 259.72M | 242.66M | 242.72M |
| OtherShortTermInvestments | 262.52M | 34.61M | 102.64M | 167.87M |
| CashAndCashEquivalents | 49.50M | 225.11M | 140.02M | 74.84M |
| CashEquivalents | 46.85M | 216.62M | 139.45M | 74.11M |
| CashFinancial | 2.65M | 8.49M | 570.00K | 734.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -118.02M | -121.33M | -122.83M | -107.76M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 161.87M | 135.51M | 130.48M | 0.00 |
| CapitalExpenditure | -15.00K | -193.00K | -6.53M | -1.65M |
| IncomeTaxPaidSupplementalData | 4.89M | 4.73M | ||
| EndCashPosition | 50.53M | 226.14M | 141.05M | 76.01M |
| BeginningCashPosition | 226.14M | 141.05M | 76.01M | 268.56M |
| EffectOfExchangeRateChanges | -15.00K | 5.00K | 1.00K | -5.00K |
| ChangesInCash | -175.60M | 85.08M | 65.04M | -192.55M |
| FinancingCashFlow | 161.21M | 135.52M | 122.91M | 1.79M |
| CashFlowFromContinuingFinancingActivities | 161.21M | 135.52M | 122.91M | 1.79M |
| NetOtherFinancingCharges | -2.26M | -555.00K | -7.99M | |
| ProceedsFromStockOptionExercised | 1.59M | 569.00K | 420.00K | 1.79M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockPayments | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 161.87M | 135.51M | 130.48M | 0.00 |
| CommonStockIssuance | 161.87M | 135.51M | 130.48M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -218.80M | 70.70M | 58.44M | -88.24M |
| CashFlowFromContinuingInvestingActivities | -218.80M | 70.70M | 58.44M | -88.24M |
| NetInvestmentPurchaseAndSale | -218.78M | 70.90M | 64.97M | -86.58M |
| SaleOfInvestment | 365.15M | 178.98M | 178.17M | 139.02M |
| PurchaseOfInvestment | -583.93M | -108.09M | -113.20M | -225.60M |
| NetPPEPurchaseAndSale | -15.00K | -193.00K | -6.53M | -1.65M |
| PurchaseOfPPE | -15.00K | -193.00K | -6.53M | -1.65M |
| OperatingCashFlow | -118.01M | -121.14M | -116.31M | -106.11M |
| CashFlowFromContinuingOperatingActivities | -118.01M | -121.14M | -116.31M | -106.11M |
| ChangeInWorkingCapital | 6.36M | -5.80M | 3.74M | 3.28M |
| ChangeInOtherCurrentLiabilities | -2.38M | -1.50M | -1.69M | 1.26M |
| ChangeInOtherCurrentAssets | -3.18M | 0.00 | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 12.23M | -5.65M | 5.89M | 4.63M |
| ChangeInAccruedExpense | 7.29M | -3.58M | 6.18M | 773.00K |
| ChangeInPayable | 4.94M | -2.08M | -287.00K | 3.86M |
| ChangeInAccountPayable | 4.94M | -2.08M | -287.00K | 3.86M |
| ChangeInPrepaidAssets | -300.00K | 1.35M | -463.00K | -2.61M |
| OtherNonCashItems | 1.30M | 1.12M | 1.21M | 1.27M |
| StockBasedCompensation | 19.43M | 18.18M | 18.52M | 16.26M |
| AmortizationOfSecurities | -9.05M | -2.55M | 73.00K | 1.25M |
| DepreciationAmortizationDepletion | 2.15M | 2.15M | 2.11M | 2.14M |
| DepreciationAndAmortization | 2.15M | 2.15M | 2.11M | 2.14M |
| NetIncomeFromContinuingOperations | -138.20M | -134.24M | -141.95M | -130.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ANNX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|